• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1265308 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type  q) v; t/ k8 U0 s* ~( B# T8 x
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 % O/ c5 \$ b. b" F! o( ]
+ Author Affiliations* e0 a" P* C( j$ z3 j

* m0 [; h1 t/ f* I1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
, l4 i0 A" U: I2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan / n. v; h: r( o( z
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 5 |2 `  I% C9 `0 z1 q; j; G& W9 a
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
' d1 f, U& F: D6 w5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
6 ^. p2 M" {) K. N) v4 {/ ^6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ! x- ^- M- n. T* Z- M
7Kinki University School of Medicine, Osaka 589-8511, Japan 6 z) G7 }: N& v1 p/ Z  ]7 I+ Z
8Izumi Municipal Hospital, Osaka 594-0071, Japan 9 D/ U, I* \; }  l0 y6 B* S6 k3 ~
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
8 w; m, j7 K9 ^% n5 s# T3 E2 e2 qCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
: f4 a; z8 L/ v% F( XAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
( t. u  s; J& K) X8 D- A
& X2 ~8 ?8 }( e6 C7 p0 K
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
# P0 X* o  j6 D& @* f7 r: m# s- o9 k: m' h0 i0 c& p9 B4 t
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
3 }  R! i7 J! X0 @$ o' o7 K5 v' Y8 n, r# t& m- v8 O
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  , X* l$ H6 D) R* v& c8 _
# s; C& f+ Z1 ~- f5 }4 q6 w3 c
Published online on: Thursday, December 1, 2011 ( `5 F# K. f# H: r0 Z
+ n4 [% ^. x& T$ A
Doi: 10.3892/ol.2011.507   s, X% e& @4 @, s; }6 q

' \+ }6 Z. N9 @- h3 B$ XPages: 405-410 ) l% l- N; j: n2 b1 D% a6 u
$ e' d9 ~, h9 V) G+ J! ~& A) x
Abstract:3 K$ X: B) o( t4 G$ |! E3 V
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
$ N1 _  u: R, O( n6 V% Z- e  C/ y 7 T, f1 [, X: g& E
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population9 Z5 z+ u: }* t: O  b( }) c
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
2 {& q' X" b; k9 M+ Author Affiliations
! k4 }9 E2 q  J1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
4 d( }2 y7 Z2 Q8 ^' c2Department of Thoracic Surgery, Kyoto University, Kyoto 4 u; a  j6 S6 F# f
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
: S4 [' K8 d  L. {" b" I1 ^& L+ e5 t&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
, X. V7 Z: X4 r: u! x! A0 rReceived September 3, 2010.
, |4 |/ {: }# l5 g- uRevision received November 11, 2010. & w  r/ E$ b6 o7 X
Accepted November 17, 2010.
) B2 D2 a! p4 b6 [) t/ YAbstract
7 [) A! ~) M2 j* L9 PBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
) e/ S% ^+ h3 b8 gPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. ( B' S6 s% t' ^4 N, q" [6 P1 E. ~
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
, s: S: Q  v. W2 ?/ i) QConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 6 Z+ a, [2 a) [4 Y) z* r
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
, M# f' J# Q5 x! C: o6 D4 C1 u. A4 T今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?3 i( ~6 P4 }! \& A6 G6 P
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
0 g, S% f/ ?5 C- dhttp://clinicaltrials.gov/ct2/show/NCT01523587
6 d. i* _1 k6 T: s5 e) A
" q9 ?: j1 U8 i" GBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
3 [7 D4 ^; Q9 W% chttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 . U) a9 J. v# W5 w. ^
& R& p  V" M9 C5 x8 i8 A
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
" U+ O1 E8 @4 A6 A0 P# ?; D至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

; q0 s! S& C1 Q# N7 O! M( g没有副作用是第一追求,效果显著是第二追求。0 a2 f, s) ^& ~" D: B
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表